Search details
1.
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
Eur Heart J
; 44(46): 4878-4889, 2023 Dec 07.
Article
in English
| MEDLINE | ID: mdl-36806405
2.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36858723
3.
Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals?
Ann Surg Oncol
; 29(13): 8002-8011, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35871672
4.
Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial.
Circulation
; 141(7): 560-570, 2020 02 18.
Article
in English
| MEDLINE | ID: mdl-32065769
5.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34120223
6.
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Oncologist
; 24(8): e646-e652, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30602614
7.
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Breast Cancer Res Treat
; 175(1): 239-246, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30721443
8.
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Breast Cancer Res Treat
; 176(2): 303-310, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-31004299
9.
Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.
Cancer
; 124(12): 2552-2560, 2018 06 15.
Article
in English
| MEDLINE | ID: mdl-29624641
10.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
N Engl J Med
; 372(2): 134-41, 2015 Jan 08.
Article
in English
| MEDLINE | ID: mdl-25564897
11.
Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
Cancer
; 123(15): 2821-2828, 2017 Aug 01.
Article
in English
| MEDLINE | ID: mdl-28323331
12.
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Oncologist
; 22(6): 642-647, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28341761
13.
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Breast Cancer Res Treat
; 166(1): 241-247, 2017 Nov.
Article
in English
| MEDLINE | ID: mdl-28710537
14.
Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
Breast Cancer Res Treat
; 165(3): 545-553, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28646344
15.
ASO Visual Abstract: Neoadjuvant Chemotherapy for Breast Cancer in the Elderly-Are We Accomplishing Our Treatment Goals?
Ann Surg Oncol
; 29(13): 8014-8015, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35902502
16.
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Oncologist
; 21(4): 418-24, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26984450
17.
Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Oncologist
; 20(10): 1105-10, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26240135
18.
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
Breast Cancer Res Treat
; 149(2): 489-95, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25552363
19.
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
Breast Cancer Res Treat
; 151(3): 589-96, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25981899
20.
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer.
Res Sq
; 2024 May 02.
Article
in English
| MEDLINE | ID: mdl-38746324